Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Antisoma presents ASA404 data

Antisoma (LSE:ASM) said data from 31 previously untreated non-small cell lung cancer (NSCLC) patients in an open-label

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE